Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -182712.72% is 628% below its 1-year average of 34595.85%, near the low end of its 1-year range (-182712.72%–97367.17%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3880.65%.
EBITDA MARGIN
-182712.72%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aspire Biopharma Holdings, Inc.
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$861915.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$874595.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.18M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
Market Cap
$840509.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$1.16M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
Market Cap
$825702.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.02M | -182712.72% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -6.76% | -0.42% | 7.09% | 7.09% |
| GlucoTrack, Inc. (GCTK)vs › | $861915.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Bone Biologics Corporation (BBLG)vs › | $874595.00 | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | -17.60% | -16.25% | -23.94% | -32.10% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $825702.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Genprex, Inc. (GNPX)vs › | $1.31M | N/A | N/A | N/A | N/A |
Gross Margin
-1.9%
EBITDA Margin
-182712.7%
Operating Margin
-312017.0%
Net Margin
-11314.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3880.65% |
| 2026-03-31 | -219.66% |
| 2025-12-31 | 97367.17% |
| 2025-09-30 | 45116.54% |
